Aethlon Medical Inc (AEMDD) 8.8200 $AEMDD
Aethlon Medical Announces Health Canada Approval of Ebola Treatment Protocol
PR Newswire - Wed May 13, 8:30AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today disclosed that the Medical Devices Bureau of Health Canada has approved a clinical study protocol to treat Ebola-infected individuals with the Aethlon Hemopurifier®. The Hemopurifier is a first-in-class affinity biofiltration device designed for the broad-spectrum elimination of viral pathogens from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other life-threatening viruses that are not addressed with proven drug therapies. Health Canada is the Federal department responsible for overseeing the health of Canadian citizens.
Aethlon Medical Announces Institutional Review Board Approval of Multi-Indication Cancer Study
PR Newswire - Tue May 12, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that the Institutional Review Board (IRB) of the University of California, Irvine (UCI) has approved a multi-indication clinical study entitled, "Plasma Exosome Concentration in Cancer Patients Undergoing Treatment."
MarketExclusive.com - Zacks Small-Cap Research Upgrades Aethlon Medical to BUY Rating and Provides Operational Update
ACCESSWIRE - Wed May 06, 10:00AM CDT
NEW YORK, NY / ACCESSWIRE / May 6, 2015 / Market Exclusive announces that Zacks Small-Cap Research has upgraded Aethlon Medical (OTCQB: AEMDD) to a Buy rating with a 12-month price target of $18.00 per share.
Aethlon Medical Announces Withdrawal of S-1 Registration Statement
PR Newswire - Mon May 04, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD, AEMDD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that on Friday, May 1, 2015, it filed with the Securities and Exchange Commission (the "SEC"
a request to withdraw its Registration Statement on Form S-1, File No. 333-203487, initially filed with the SEC on April 17, 2015. The Company requested to withdraw its Registration Statement due to market conditions and for broader strategic reasons.
Aethlon Medical Discloses Presentation of Preliminary CTE Related Study Results
PR Newswire - Thu Apr 16, 11:01AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD, AEMDD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that Dr. Robert Stern, professor of neurology, neurosurgery, and anatomy and neurobiology at Boston University School of Medicine (BUSM) has presented preliminary, unpublished findings related to research being conducted by Aethlon Medical's majority owned subsidiary, Exosome Sciences, Inc. The presentation was given earlier today at the 5th Annual Traumatic Brain Injury Conference being held in Washington, D.C.
Aethlon Medical Announces Cancer Clinical Trial Agreement
PR Newswire - Wed Apr 15, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it has entered into an investigator-initiated clinical trial agreement with the University of California, Irvine (UCI). Under the agreement, a clinical study protocol entitled, "Plasma Exosome Concentration in Cancer Patients Undergoing Treatment," will seek to enroll five individuals in each of nine defined tumor types for a total study population of up to 45 subjects. The tumor types include the following forms of cancer; Breast adenocarcinoma, Colorectal, Gastric & Gastroesophageal, Pancreatic, Cholangiocarcinoma, Lung (NSCLC), Head & Neck (SCC), Melanoma and Ovarian adenocarcinoma. The principal investigator of the study is Edward Nelson, M.D.
Aethlon Medical Announces Health Canada Approval of Ebola Treatment Protocol
PR Newswire - Wed May 13, 8:30AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today disclosed that the Medical Devices Bureau of Health Canada has approved a clinical study protocol to treat Ebola-infected individuals with the Aethlon Hemopurifier®. The Hemopurifier is a first-in-class affinity biofiltration device designed for the broad-spectrum elimination of viral pathogens from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other life-threatening viruses that are not addressed with proven drug therapies. Health Canada is the Federal department responsible for overseeing the health of Canadian citizens.
Aethlon Medical Announces Institutional Review Board Approval of Multi-Indication Cancer Study
PR Newswire - Tue May 12, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that the Institutional Review Board (IRB) of the University of California, Irvine (UCI) has approved a multi-indication clinical study entitled, "Plasma Exosome Concentration in Cancer Patients Undergoing Treatment."
MarketExclusive.com - Zacks Small-Cap Research Upgrades Aethlon Medical to BUY Rating and Provides Operational Update
ACCESSWIRE - Wed May 06, 10:00AM CDT
NEW YORK, NY / ACCESSWIRE / May 6, 2015 / Market Exclusive announces that Zacks Small-Cap Research has upgraded Aethlon Medical (OTCQB: AEMDD) to a Buy rating with a 12-month price target of $18.00 per share.
Aethlon Medical Announces Withdrawal of S-1 Registration Statement
PR Newswire - Mon May 04, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD, AEMDD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that on Friday, May 1, 2015, it filed with the Securities and Exchange Commission (the "SEC"
a request to withdraw its Registration Statement on Form S-1, File No. 333-203487, initially filed with the SEC on April 17, 2015. The Company requested to withdraw its Registration Statement due to market conditions and for broader strategic reasons. Aethlon Medical Discloses Presentation of Preliminary CTE Related Study Results
PR Newswire - Thu Apr 16, 11:01AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD, AEMDD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that Dr. Robert Stern, professor of neurology, neurosurgery, and anatomy and neurobiology at Boston University School of Medicine (BUSM) has presented preliminary, unpublished findings related to research being conducted by Aethlon Medical's majority owned subsidiary, Exosome Sciences, Inc. The presentation was given earlier today at the 5th Annual Traumatic Brain Injury Conference being held in Washington, D.C.
Aethlon Medical Announces Cancer Clinical Trial Agreement
PR Newswire - Wed Apr 15, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it has entered into an investigator-initiated clinical trial agreement with the University of California, Irvine (UCI). Under the agreement, a clinical study protocol entitled, "Plasma Exosome Concentration in Cancer Patients Undergoing Treatment," will seek to enroll five individuals in each of nine defined tumor types for a total study population of up to 45 subjects. The tumor types include the following forms of cancer; Breast adenocarcinoma, Colorectal, Gastric & Gastroesophageal, Pancreatic, Cholangiocarcinoma, Lung (NSCLC), Head & Neck (SCC), Melanoma and Ovarian adenocarcinoma. The principal investigator of the study is Edward Nelson, M.D.
